Sandoz Group AG
Company Snapshot
Founded: 1886
Entity Type: Public
Employees: 22,049
Region: Europe
Revenue: $10,357.0 Millions
Revenue Year: 2024
Headquarter: Basel, Switzerland
Key Geographics: North America, Europe, International
Corporate Address: Centralbahnstrasse 4 4051 Basel Switzerland www.sandoz.com
Company Overview
Sandoz operates in three business segments: retail generics, biopharmaceuticals, and anti-infectives. Retail Generics include finished dosage forms of small-molecule pharmaceuticals. Sandoz offers protein- and other biotechnology-based products in Biopharmaceuticals, including biosimilars and biotechnology manufacturing services to other companies. In Anti-Infectives, Sandoz manufactures and supplies APIs and intermediates. The company offers over 1,500 products to nearly 500 million patients in more than 100 countries. In October 2023, Sandoz became a standalone company after separation from Novartis. The company shifted its headquarters to Basel, Switzerland.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Sandoz Group AG In Reports
Sandoz Group AG In News
Company's Business Segments
- Biosimilar and Generic Medicines : The company manufactures and distributes generic and biosimilar medicines for treating patients with cancer, diabetes, and arthritis.
Applications/End User Industries
- Healthcare
- Pharmaceuticals
- Biosimilars
- Medicines
- Generic Medicines
BCC Research Beacon 